You are on page 1of 6

Arthritis Care & Research Vol. 64, No. 6, June 2012, pp 935940 DOI 10.1002/acr.

21645 2012, American College of Rheumatology


A Case of Refractory Rheumatoid Pericarditis



CASE PRESENTATION History of the Present Illness

A 63-year-old man with an outside diagnosis of rheumatoid arthritis (RA) presented to our medical center for new-onset, progressively worsening dyspnea (New York Heart Association class IV), abdominal bloating, and peripheral edema for 3 4 weeks prior to presentation. A chest radiograph showed mild enlargement of the cardiac silhouette with pulmonary venous hypertension, mild pulmonary edema, and small pleural effusions. Electrocardiogram showed atrial utter with a 3:1 atrioventricular conduction, left anterior fascicular block, and a prolonged QT interval. A transthoracic echocardiogram (TTE) revealed severe constrictive pericarditis (CP) with pronounced diastolic ow reversal in the hepatic veins. There was no evidence of an intracardiac mass or thrombus. The left ventricular ejection fraction was normal at 70%. He was hospitalized for further evaluation of congestive heart failure (CHF).

Medical and Surgical History

He had well-controlled hypertension and hyperlipidemia. There was no history of coronary artery disease, cardiac arrhythmias, acute pericarditis, or CHF. RA was diagnosed 20 years prior with predominantly large joint involvement (hips and ankles) in the setting of elevated inammatory markers and a positive rheumatoid factor (RF). He was originally treated with methotrexate that was discontinued for unknown reasons. Azathioprine and adalimumab were used briey and discontinued due to inefcacy. He eventually underwent bilateral total hip arthroplasties but had no apparent extraarticular manifestations until his current presentation.

Medications Prior to Presentation

The patient was taking aspirin 325 mg daily, nebivolol 5 mg daily, simvastatin 40 mg at bedtime, pantoprazole 40 mg daily, vitamin D 400 IU, and a multivitamin. For RA, he was receiving prednisone 8 mg daily and celecoxib 200 mg once daily.

Physical Examination
Upon arrival at our hospital, the patient was alert and oriented, but appeared fatigued and deconditioned. His blood pressure was 128/88 mm Hg, pulse was 80 98 beats/ minute, and oxygen saturation was 94% on oxygen 3 liters/ minute by nasal cannula. His jugular venous pressure was elevated. Lung elds showed coarse crepitations at the bases bilaterally. Cardiac examination revealed a 2 right ventricular heave and normal S1 and S2 with intermittent diastolic lling sounds at the apex. No arterial bruits were evident and peripheral pulses were normal. Lower extremities had pitting edema up to the thighs. Mild ascites was noted on the abdominal examination. No hepatosplenomegaly or lymphadenopathy was detected. The skin and neurologic examination was normal. The joint examination did not show any evidence of active synovitis.

Family and Social History

He was married and worked full time. He smoked up to 15 cigars in a year and drank beer 3 4 times a week. He had a family history of premature coronary artery disease in his father (diagnosed in his 50s), who died from colon cancer.

Review of Systems
His symptoms were not preceded by a viral prodrome. He denied rhinorrhea, cough, chest discomfort, palpitations, orthopnea, paroxysmal nocturnal dyspnea, syncope, or presyncopal episodes. He admitted to worsening fatigue and decreasing appetite over the 3 months prior to admission but denied fever, chills, or night sweats. He also denied any history of skin rash, photosensitivity, alopecia, oral/nasal/genital/cutaneous ulcers, sicca symptoms, inammatory eye symptoms, pleurisy, pericarditis, hemoptysis, epistaxis, recurrent sinusitis, abdominal pain, or other bowel bladder symptoms. He did not report any focal neurologic decits.

Ashima Makol, MD, Joseph J. Maleszewski, MD, Kenneth J. Warrington, MD: Mayo Clinic, Rochester, Minnesota. Address correspondence to Ashima Makol, MD, Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. E-mail: Submitted for publication December 23, 2011; accepted in revised form February 10, 2012.

Diagnostic Evaluation
Laboratory studies were pertinent for a normocytic anemia (hemoglobin 12.8 gm/dl), leukocytosis (white blood cells 935


Makol et al week and subsequently rituximab (1 gm intravenously, 2 weeks apart), with which his joint symptoms improved signicantly. In the subsequent 4 weeks, he lost another 40 pounds (a total of 70 pounds over 1 year). He was hospitalized with an acute exacerbation of his CHF symptoms and severe fatigue. He had a syncopal episode due to tachy-brady syndrome and underwent a pacemaker placement. His anemia worsened (hemoglobin 9.6 gm/dl) and the CRP level continued to rise (99.5 mg/liter). For evaluation of an underlying malignancy, computed tomography (CT) of the chest, abdomen, and pelvis was obtained and showed sub centimeter-sized mediastinal and retroperitoneal adenopathy. Positron emission tomography was negative for malignancy or large-vessel vasculitis. An upper gastrointestinal (GI) endoscopy and colonoscopy were essentially unrevealing and consistent with the patients lack of GI symptoms. Small bowel biopsy did not show changes of celiac disease or identiable microorganisms. Peripheral blood polymerase chain reaction (PCR) for Tropheryma whipplei was negative on 2 separate tests. TTE showed an ejection fraction of 70%, thickened pericardium, and restrictive physiology. His progressive weight loss and cachexia were attributed to CHF and chronic inammation. Several weeks later, the patient reported a change in his bowel habits with loose stools and large-volume bowel movements. He denied hematochezia or melena. Given the constellation of arthritis, weight loss, diarrhea, and cardiac involvement, Whipples disease (WD) was again considered in the differential diagnosis.

Figure 1. A, Computed tomography of the chest demonstrating postoperative changes of pericardiectomy with thickening of the residual pericardium (arrow). B, Cardiac magnetic resonance imaging demonstrates thickening and enhancement of the residual pericardium (arrow).

12.6 109/liter), elevated brain natriuretic peptide (BNP) of 2,491 pg/ml (normal range 10 83), and a high Creactive protein (CRP) level of 87.2 mg/liter (normal value 8). Antinuclear antibody, extractable nuclear antigen panel, RF, anti cyclic citrullinated peptide antibody, antineutrophil cytoplasmic antibody, serum protein electrophoresis, serum urate, QuantiFeron test for Mycobacterium tuberculosis, human immunodeciency virus (HIV) serology, urinalysis, blood cultures, and liver, kidney, and thyroid function testing were normal or negative. Hand and foot radiographs conrmed marginal erosions at the distal ulnar, metacarpal, and metatarsal heads, supporting the diagnosis of RA. Cardiac catheterization showed patent coronary arteries. The patient underwent diuresis, successful cardioversion, and a radical pericardiectomy. Initial histologic evaluation of the resected pericardium showed nonspecic features of brous thickening and nongranulomatous lymphoplasmacytic and neutrophilic inltrates without rheumatoid nodules. These histologic changes were initially thought to be consistent with the clinical diagnosis of RA.

CP can occur following virtually any pericardial disease process, but rarely follows recurrent episodes of acute pericarditis. The most common etiologies found in large case series (15) include (Table 1) idiopathic/postviral infection, post cardiac surgery, postradiation therapy to
Table 1. Differential diagnosis of constrictive pericarditis 1. 2. 3. Idiopathic/viral Postcardiac surgery Postmediastinal radiation therapy (for Hodgkins lymphoma, breast cancer, and esophageal or metastatic testicular cancer) Postmyocardial infarction (Dresslers syndrome) Infectious: tuberculosis (most common), purulent (Staphylococcus aureus, Streptococcus pyogenes, Clostridium sordellii), fungal (Candida), parasitic (Chagas disease) Chronic renal failure (uremic pericarditis) Connective tissue disorders and rheumatic disease (systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, systemic sclerosis, Behc ets disease) Neoplastic pericardial inltration (atrial myxoma, mesothelioma) Miscellaneous (asbestosis, sarcoidosis, posttraumatic, Erdheim-Chester disease, amyloidosis, familial Mediterranean fever, graft-versus-host disease, etc.)


The patients CP was attributed as an extraarticular manifestation of his RA. Treatment for RA was not modied given the absence of active synovitis and postsurgical status. However, over the next 4 months, he experienced an unintentional weight loss of 30 pounds and developed right ankle synovitis. The CRP level remained persistently elevated at 75.7 mg/liter and the BNP increased to 4,665 pg/ml. Heart failure symptoms that had improved initially recurred again. Cardiac examination revealed a new pericardial rub. A cardiac magnetic resonance image (Figure 1) showed persistent soft tissue thickening in the surgical bed and enhancement of the residual pericardium, suggesting ongoing pericardial inammation. Functional imaging showed abnormal ventricular septal motion (dshaped ventricular septum in early diastole) suggestive of a constrictive physiology without denite evidence for ventricular interdependence. Ventricle size and systolic function were normal. Mild tricuspid, aortic, and mitral regurgitation were noted. There was no abnormal myocardial delayed enhancement to suggest infarct, inammation, or myocardial brosis. His immunosuppressive regimen was then intensied to include methotrexate 15 mg/

4. 5.

6. 7.

8. 9.

Clinicopathologic Conference the mediastinum, postinfectious (tuberculous or purulent), rheumatic diseases (including RA, systemic lupus erythematosus, mixed connective tissue disease, and dermatomyositis, among others), and other miscellaneous causes (such as malignancy, sarcoidosis, asbestosis, and trauma). The diagnoses we considered in this patient are listed below.


Pericarditis is the most common cardiac manifestation of RA (up to 40% of patients in autopsy studies), but only 2% develop clinical symptoms. CP occurs as an infrequent yet life-threatening sequela. Affected patients are frequently seropositive and present with dyspnea, orthopnea, cough, chest discomfort, and peripheral edema. The onset of CP does not seem to correlate with the disease duration or severity of arthritis and may occur even when RA is quiescent or well controlled. The diagnosis of CP is established by echocardiography or CT, and merits urgent treatment to avoid catastrophic hemodynamic consequences. Surgery is the only denitive treatment option, but concomitant immunosuppression (with steroids, diseasemodifying antirheumatic drugs, or biologics) is often equally important to control inammation. In patients unresponsive to standard treatment, a comprehensive evaluation to determine possible alternate etiologies for their refractoriness is necessary. A particularly concerning etiology in the setting of immunosuppression is infection.

Figure 2. Photomicrograph of parietal pericardial tissue showing numerous periodic acidSchiff (PAS)positive (magenta colored) organisms within macrophages with an accompanying lymphoplasmacytic inltrate (PAS stained; original magnication 400).

plei by PCR. The patient was diagnosed with CP secondary to WD and Whipples arthropathy.

In 1907, Whipple described the case of a 36-year-old physician who died after 5 years of polyarthritis, chronic diarrhea, abdominal pain, and weight loss (7). Postmortem examination showed fat deposition in the intestinal mucosa and mesenteric and retroperitoneal lymph nodes that he termed intestinal lipodystrophy. WD, as it is now called, is a rare multisystemic chronic infectious disease clinically characterized by a triad of diarrhea, abdominal pain, and weight loss. It was considered uniformly fatal until microscopic visualization of a bacterial organism led to the rst successful treatment with chloramphenicol by Paulley in 1952 (8). In 1961, the bacterium was visualized in macrophages by electron microscopy (9). It was later identied as a gram-positive actinomycete and given the name Tropheryma whippelii (in Greek, Trophe means nourishment and eryma means barrier), representing the malabsorption associated with WD. It is ubiquitous in the environment often found in soil. In 1992, PCR enabled amplication of the bacteriums 16S ribosomal RNA from duodenal lesions, and successful in vitro culture of the slow-growing bacillus in 2000 (10) led to a major breakthrough in the understanding of pathogenesis, diagnosis, and treatment. Its name was ofcially changed to T whipplei (Whipples bacillus) in 2001 and genomic sequencing was completed in 2003. WD is uncommon, with approximately 1,000 cases reported until 2007 (11). It has intrigued many clinicians and pathologists and has been detected only in cases where it was suspected or sought. There is a long prodromal period (6.7 years) (12) and clinical manifestations overlap with many chronic inammatory diseases, making early diagnosis difcult. The majority of patients are middle-aged white men (mean age 49 years) (13). GI involvement is the most common presentation and may include

Tuberculosis (TB) is the most common infectious cause of CP worldwide, but the incidence is much lower in developed nations. It is more frequent among those receiving immunosuppression or those with HIV. Our patient did not have any prior exposure to TB and was checked for latent TB with a QuantiFeron test for M tuberculosis and HIV serology, which were negative. Other rare infectious etiologies include parasitic, fungal, and purulent pericarditis. Our patient had negative bacterial and fungal blood cultures. WD is a rare multisystem infectious disease caused by T whipplei, commonly presenting with abdominal pain, diarrhea, weight loss, arthritis, and neurologic symptoms. Previously found on autopsy studies, cardiac involvement in WD is now being increasingly recognized, manifesting as endocarditis, and/or less often, myocarditis or CP. Our patient did not have GI symptoms until later in his course. Peripheral blood PCR for WD was negative and a small bowel biopsy was negative for T whipplei organisms. There are a few reported cases of patients with inammatory arthritides who deteriorated dramatically on biologic therapy and were eventually found to have WD that was masquerading as RA or spondylarthropathy (6).

The pericardial tissue obtained at pericardiectomy was retrieved and evaluated with a periodic acidSchiff (PAS) stain. Numerous PAS-positive microorganisms were seen in macrophages (Figure 2) that were conrmed as T whip-

938 chronic diarrhea, abdominal pain, mesenteric/retroperitoneal lymphadenopathy, ascites secondary to hypoalbuminemia, and a wasting syndrome. There are no specic blood tests or serologic markers, although nonspecic acute-phase reactants may be elevated. The gold standard test for diagnosis is an upper GI endoscopy with multiple small bowel biopsies. Pale yellow, shaggy mucosa alternating with erythematous, friable mucosa may be seen endoscopically in the duodenum or jejunum (11). Histologic evaluation with PAS staining reveals magenta inclusions within macrophages, but these are nonspecic and may be seen in other diseases such as Mycobacterium avium complex. PCR-based testing for T whipplei DNA is needed for conrmation. It is also important to remember that there is a considerable number of patients who have WD without GI involvement, and those may be missed when using the gold standard test. When performed on peripheral blood, PCR has a much lower sensitivity than when done on an involved tissue site (duodenum, lymph node, heart valve, cerebrospinal uid, synovial uid/tissue) (11). GI symptoms may be absent in one-quarter of patients (14) at disease onset. Neurologic involvement occurs late and usually as part of a recurrence or relapse in inadequately treated patients. Joint manifestations are seen in up to 67% of patients and may precede typical GI symptoms for up to 8 years (15). These include migratory arthralgias involving large joints, nondeforming seronegative oligo-/polyarthritis, spondylodiscitis, spondylarthropathy, or rarely erosive arthritis closely resembling RA. WD can therefore mimic RA for several years before displaying symptoms associated with visceral involvement. Immunosuppression with biologic response modiers (antitumor necrosis factor [anti-TNF] therapy, rituximab, etc.) can exacerbate preexisting WD and trigger visceral presentation, as in our patient (6,15). It therefore becomes necessary to consider this rare yet curable infectious disease in middle-aged men with RF-negative longterm arthritis that is resistant to standard therapy, particularly prior to starting biologics. It must be specically sought by obtaining and/or repeating appropriate tissue (duodenal or synovial biopsy with PAS staining and PCR) or uid (synovial uid PCR) for testing. In 1952, Upton rst reported cardiac involvement as a component of WD (16). The presence of a pericardial rub and signs of CHF or systolic heart murmurs may be early clinical signs of cardiac involvement. Enzinger reported PAS-positive structures within endocardial vegetations in 34% (32 of 94) of autopsied patients with WD (17). Cardiac involvement in WD is common and may involve any of the 3 layers of the heart. It has been reported in up to 1755% (18,19) of patients with WD. Pancarditis was detected on autopsy in up to two-thirds of patients in one series (20). WD should also be considered in the differential diagnosis of patients with culture-negative endocarditis. McAllister and Fenoglio (21) described 19 male patients with WD, 56% of whom had clinical cardiac ndings. Seventy-nine percent had gross cardiac lesions at autopsy, with pericardial adhesions in 79%, valvular brosis/deformity in 53%, and myocardial brosis in 11%. The mitral valve was thickened and deformed in all 10 patients with valvular

Makol et al involvement. All cardiac specimens had macrophages containing PAS-positive structures, and electron microscopy demonstrated rod-shaped organisms in the cardiac valves and myocardium. Coronary arteritis (22), aortitis (23), pulmonary hypertension (24), myocarditis (lymphocytic and granulomatous), and sudden death (25) have also been reported with cardiac WD. No clear relationship between the extent of cardiac involvement and the duration or severity of the systemic disease has been shown (21), and the efcacy of antibiotic treatment for cardiac lesions remains to be demonstrated. Most patients evolve to needing surgery, but CHF responsive to antibiotics has been reported (26). The complications of cardiac involvement can be potentially fatal, warranting early diagnosis and treatment. CP is one such complication seen with untreated WD and can mimic rheumatoid CP, particularly in patients with concomitant arthritis. Patients present with dyspnea, peripheral edema, ascites, or pleural effusions. These can often be overlooked or attributed to other factors such as anemia or hypoalbuminemia secondary to malabsorption in patients with WD (21). Examination may show elevated jugular venous pressure, pericardial rub, or cardiac murmurs. TTE reveals thickened pericardium and restrictive physiology. CT can also demonstrate pericardial thickening and calcication. Only 6 cases of WD associated with CP have been reported in the literature until 2009, but none with CP as the presenting manifestation. Denitive treatment is radical pericardiectomy. Fibrinous pericarditis with dense adhesions, brosis, and inammation has been described on histopathologic examination of pericardial tissue in WD, which also often shows PAS-positive structures within macrophages. Again, PCR performed on the parafn-embedded tissue may help to conrm the presence of T whipplei. Surgery should be followed by antibiotic therapy to prevent recurrence or relapse, particularly central nervous system disease. Intravenous ceftriaxone (2 gm/day) or streptomycin (1 gm/day) with penicillin G (1.2 million units/day) for 14 days followed by trimethoprim/sulfamethoxazole (160/800 mg/day) for at least 12 years is the standard regimen (13). These are favored because they cross the blood brain barrier. Alternatively, a combination of doxycycline (200 mg/day) with hydroxychloroquine (200 mg 3 times a day; alkalinizing agent) for 12 years may be used (13). This regimen works by increasing the intravacuolar pH, making it bactericidal for the organism, which usually requires an acidic pH to remain viable in vitro. Recurrences have been reported despite adequate treatment with any of the above regimens. There is no serologic marker that can help determine the appropriate duration of treatment and the patient needs to be followed clinically. It is uncertain if antibiotics can prevent Whipples pericarditis from progressing to constriction if started early in the course, and further studies to ascertain this are needed. WD, like any other infection, can progress in the setting of immunosuppression. We suspect this is what actually led to the diagnosis in our patient. He rapidly developed GI manifestations for the rst time after initiation of rituximab, which prompted careful reevaluation and eventual

Clinicopathologic Conference


Figure 3. C-reactive protein (CRP) trend over time. The CRP level was persistently elevated during the patients clinical course until antibiotics were started and showed a declining trend thereafter. This was also accompanied by rapid clinical improvement.

diagnosis of WD. Interestingly, however, the small bowel biopsy did not demonstrate changes of WD, which may have been due to very early disease in the bowel. Similar exacerbation of visceral symptoms leading to the diagnosis of WD has been noted upon initiating anti-TNF therapy for presumed RA (6). To summarize, WD is an often overlooked etiology of oligo-/polyarthritis and must be considered when evaluating and treating middle-aged white men with seronegative RA. WD is a systemic disease and presents without GI symptoms in up to 25% of patients. Patients with unusual and refractory extraarticular manifestations, especially occurring in the context of a seronegative arthropathy, should prompt consideration of alternative diagnoses and must be evaluated for possible WD. A thorough search for WD should be considered prior to starting biologic therapy because this may lead to progressive manifestations of WD. Efforts to recognize and treat this potentially fatal infection early can help prevent life-threatening complications.

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the nal version to be published. Dr. Makol had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design. Makol, Warrington. Acquisition of data. Makol, Maleszewski. Analysis and interpretation of data. Makol, Maleszewski, Warrington.

1. Bertog SC, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, et al. Constrictive pericarditis: etiology and cause-specic survival after pericardiectomy. J Am Coll Cardiol 2004;43:144552. 2. Cameron J, Oesterle SN, Baldwin JC, Hancock EW. The etiologic spectrum of constrictive pericarditis. Am Heart J 1987; 113:354 60. 3. Imazio M, Brucato A, Mayosi BM, Derosa FG, Lestuzzi C, Macor A, et al. Medical therapy of pericardial diseases: part II. Noninfectious pericarditis, pericardial effusion and constrictive pericarditis. J Cardiovasc Med (Hagerstown) 2010;11: 78594. 4. Imazio M, Brucato A, Mayosi BM, Derosa FG, Lestuzzi C, Macor A, et al. Medical therapy of pericardial diseases: part I. Idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) 2010;11:71222. 5. Ling LH, Oh JK, Schaff HV, Danielson GK, Mahoney DW, Seward JB, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation 1999;100:1380 6. 6. Hoppe E, Masson C, Audran M, Drillon M, Andreu M, Saraux A, et al. Whipples disease diagnosed during biological treatment for joint disease. Joint Bone Spine 2010;77: 3359. 7. Whipple G. A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acid in the intestinal and mesentericlymphatic tissues. Bull Johns Hopkins Hosp 1907;18:38291.

The patient received 2 weeks of intravenous ceftriaxone followed by oral trimethoprim/sulfamethoxazole for a year. Immunosuppressive therapy was discontinued and prednisone was gradually tapered off. Over the next several months, he gained weight and his dyspnea, peripheral edema, fatigue, and synovitis improved remarkably. After 1 year of antibiotic therapy, he was asymptomatic. BNP improved to 459 pg/ml and the CRP level was 7.8 mg/liter (Figure 3). A subsequent CT scan of the chest and abdomen showed resolution of the mediastinal and retroperitoneal adenopathy.

8. Paulley JW. A case of Whipples disease (intestinal lipodystrophy). Gastroenterology 1952;22:128 33. 9. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identication of the uncultured bacillus of Whipples disease. N Engl J Med 1992;327:293301. 10. Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, et al. Cultivation of the bacillus of Whipples disease. N Engl J Med 2000;342:620 5. 11. Fenollar F, Puechal X, Raoult D. Whipples disease. N Engl J Med 2007;356:55 66. 12. Puechal X. Whipple disease and arthritis. Curr Opin Rheumatol 2001;13:74 9. 13. Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D. Whipples disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 2008;8:179 90. 14. Elkins C, Shuman TA, Pirolo JS. Cardiac Whipples disease without digestive symptoms. Ann Thorac Surg 1999;67: 250 1. 15. Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T. Immunosuppressive therapy in Whipples disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol 2005;100:116773. 16. Upton AC. Histochemical investigation of the mesenchymal lesions in Whipples disease. Am J Clin Pathol 1952;22:755 64. 17. Enzinger FH. Whipples disease: a review of the literature and report of 15 patients. Virchows Arch Pathol Anat 1963;336: 238 68.

Makol et al
18. Durand DV, Lecomte C, Cathebras P, Rousset H, Godeau P, for the SNFMI Research Group on Whipple Disease and Societe Nationale Francaise de Medecine Interne. Whipple disease: clinical review of 52 cases. Medicine (Baltimore) 1997;76: 170 84. 19. Fenollar F, Lepidi H, Raoult D. Whipples endocarditis: review of the literature and comparisons with Q fever, Bartonella infection, and blood culture-positive endocarditis. Clin Infect Dis 2001;33:1309 16. 20. Vlietstra RE, Lie JT, Kuhl WE, Danielson GK, Roberts MK. Whipples disease involving the pericardium: pathological conrmation during life. Aust N Z J Med 1978;8:649 51. 21. McAllister HA Jr, Fenoglio JJ Jr. Cardiac involvement in Whipples disease. Circulation 1975;52:152 6. 22. James TN, Bulkley BH. Abnormalities of the coronary arteries in Whipples disease. Am Heart J 1983;105:48191. 23. Feldman M. Whipples disease. Am J Med Sci 1986;291:56 67. 24. Bostwick DG, Bensch KG, Burke JS, Billingham ME, Miller DC, Smith JC, et al. Whipples disease presenting as aortic insufciency. N Engl J Med 1981;305:995 8. 25. Mooney EE, Kenan DJ, Sweeney EC, Gaede JT. Myocarditis in Whipples disease: an unsuspected cause of symptoms and sudden death. Mod Pathol 1997;10:524 9. 26. Kraunz RF. Whipples disease with cardiac and renal abnormalities. Arch Intern Med 1969;123:701 6.